Titled "Utility and first clinical application of screening embryos for polygenic disease risk reduction", ORIGINAL RESEARCH ARTICLE published in Frontiers in Endocrinology
How can the benefit of PGT-P be quantified? One metric is Relative Risk Reduction, or RRR, illustrated with this example of several thousand adult siblings assembled as a type 1 diabetes high risk cohort - families with family history of the disease.
"Genomic Prediction of 16 Complex Disease Risks Including Heart Attack, Diabetes, Breast and Prostate Cancer" Louis Lello et al. 2019
"Genomic Prediction is, however, offering something more wide-ranging. It is screening embryos for almost 1m single-nucleotide polymorphisms (snps). These are places where individual genomes routinely differ from one another at the level of an individual genetic letter. Individual snp differences between people rarely have much effect. But add them up and they can raise or lower by quite a lot the likelihood of someone suffering a particular disease. Generate several embryos and snp-test them, then, and you can pick out those that you think will grow up to be the healthiest."
Using the title "The world’s first Gattaca baby tests are finally here", the article exclusively explores critical perspectives on polygenic screening of embryos, without printing any of the responses given to these perspectives.
The CAP accreditation – and the Clinical Laboratory Improvement Amendments (CLIA) certification that Genomic Prediction Clinical Laboratory achieved in 2019 – are internationally recognized credentials awarded to laboratories complying with the most comprehensive, rigorous and scientifically-endorsed standards of laboratory practice.
Preimplantation genetic testing (PGT) has demonstrated clinical utility for aneuploidy screening, monogenic disorders, and structural rearrangements. Polygenic disorders including cancer, diabetes, and heart disease affect more than 25% of the human population.
In a panel named "Genomic Prediction of Complex Traits and Disease Risks", prof. Hsu fields questions from CRISPR inventor Dr. Jennifer Doudna and Berkeley scholars